Compounding shortages and the 503A exception: how the law actually works
The phrase “shortage loophole” implies something shady. The legal mechanism is actually straightforward — and understanding it matters for patients.
TL;DR
- When a drug is on the FDA drug shortage list, a 503A pharmacy can legally compound it for individual patients with a valid prescription.
- The exception ends when the FDA removes the drug from the shortage list — which is what happened with GLP-1 drugs in early 2025.
- A compounded drug is not a generic and is not FDA-approved. It is prepared under a different legal framework.
What it is
The Drug Quality and Security Act (DQSA — the 2013 federal law that modernized compounding rules) includes a provision: if the FDA declares a drug to be in shortage, state-licensed 503A pharmacies may compound that drug. Think of it as a pressure-relief valve — the law acknowledges that when a patient can’t access a drug through normal channels, compounding fills the gap.
This is not a loophole. It is an explicit provision in the statute.
How it works
The FDA maintains an official drug shortage list. When a drug appears on that list, the shortage exception is active. A 503A pharmacy with a valid patient prescription can compound that drug — sourcing the active pharmaceutical ingredient (the raw API) from an FDA-registered supplier, following USP 797 sterile compounding standards, and dispensing to the patient.
When the FDA removes the drug from the shortage list, the exception ends. The pharmacy must stop compounding it.
Why it mattered for GLP-1 drugs
Semaglutide (brand name Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) were placed on the FDA shortage list due to supply constraints. This is the legal basis on which hundreds of compounding pharmacies began preparing compounded GLP-1 medications — and why millions of patients were able to access them at lower cost.
The FDA removed semaglutide and tirzepatide from the shortage list in late 2024 and early 2025. That ended the shortage-exception basis. Legal challenges followed, and the situation remains contested. For current status, check FDA’s GLP-1 shortage page directly.
What to know before considering it
The shortage exception is real and legal when it applies. But “legal during the shortage” and “legal today” are different statements. The basis for compounding must match the current regulatory status of the drug. Any pharmacy compounding a drug outside the applicable exception is operating outside the law.
Always confirm the current shortage status and the pharmacy’s compliance posture before starting a compounded protocol. See our overview of 503A vs. 503B pharmacies for the broader framework.
The Halftime POV
We think this area of pharmaceutical law deserves plain-English explanation. Patients who accessed compounded semaglutide during the shortage did so through a legal mechanism — not a gray market workaround. Understanding the distinction protects you from bad actors who blur the line between the shortage exception and genuinely unregulated compounds.
Related reading:
- 503A vs. 503B compounding pharmacies: what the difference means for patients
- The 503A compounding process explained
- Gray-market peptides: what the risks actually are
FAQ
Q: What is the 503A shortage exception? A: It’s a provision in the Drug Quality and Security Act that allows licensed 503A compounding pharmacies to compound a drug for individual patients when the FDA places that drug on its official shortage list. It ends when the drug is removed from the list.
Q: Is compounded semaglutide still legal in 2026? A: The shortage exception for semaglutide and tirzepatide ended after FDA removed them from the shortage list in 2024–2025. The current legality of compounding these drugs depends on ongoing litigation and any updated FDA guidance. Check current FDA.gov status for the most accurate answer.
Q: Is a compounded medication FDA-approved? A: No. Compounded medications are not FDA-approved. They are prepared under FDA oversight of the compounding framework but are not individually reviewed and approved the way branded drugs are.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
